Top

Published in:

01-08-2006 | Original

Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock

Authors: Guillaume Monneret, Alain Lepape, Nicolas Voirin, Julien Bohé, Fabienne Venet, Anne-Lise Debard, Hélène Thizy, Jacques Bienvenu, François Gueyffier, Philippe Vanhems

Published in: Intensive Care Medicine | Issue 8/2006

Abstract

Objective

The immediate overwhelming release of inflammatory mediators in septic shock is rapidly followed by strong anti-inflammatory responses inducing a state of immunosuppression. The patients who survive the initial hyper-inflammatory step of septic shock but subsequently die may be those who do not recover from immunosuppression. We assessed whether a low monocyte human leukocyte antigen-DR (mHLA-DR) expression, proposed as a marker of immunosuppression, is an independent predictor of mortality in patients who survived the initial 48 h of septic shock.

Design and setting

Prospective observational study performed in two adult intensive care units at a university hospital.

Patients

93 consecutive patients with septic shock.

Measurements and results

At days 1–2, mHLA-DR values (determined by flow cytometry) were not significantly different between survivors and non-survivors. A sharp difference became highly significant at days 3–4 when survivors had increased their values, while non-survivors had not (43% vs. 18%, percentage of HLA-DR positive monocyte, p < 0.001). Multivariate logistic regression analysis revealed that low mHLA-DR (< 30%) at days 3–4 remained independently associated with mortality after adjustment for usual clinical confounders, adjusted odds ratio (CI): 6.48 (95% CI: 1.62–25.93).

Conclusion

The present preliminary results show that mHLA-DR is an independent predictor of mortality in septic shock patients. Being a marker of immune failure, low mHLA-DR may provide a rationale for initiating therapy to reverse immunosuppression. After validation of the current results in multicenter studies, mHLA-DR may help to stratify patients when designing a mediator-directed therapy in a time-dependent manner.

Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated cost of care. Crit Care Med 29:1303–1310PubMedCrossRef

Annane D, Bellissant E, Cavaillon JM (2005) Septic shock. Lancet 365:63–78PubMedCrossRef

Reddy RC, Chen GH, Tekchandani PK, Standiford TJ (2001) Sepsis-induced immunosuppression: from bad to worse. Immunol Res 24:273–287PubMedCrossRef

Hotchkiss RS, Karl EI (2003) The pathophysiology and treatment of sepsis. N Engl J Med 348:138–150PubMedCrossRef

Munford RS, Pugin J (2001) Normal response to injury prevents systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 163:316–321PubMed

Haveman JW, Muller Kobold AC, Tervaert JW, van den Berg AP, Tulleken JE, Kallenberg CG, The TH (1999) The central role of monocytes in the pathogenesis of sepsis: Consequences for immunomonitoring and treatment. Neth J Med 55:132–141PubMedCrossRef

Hershman MJ, Cheadle WG, Wellhausen SR, Davidson PF, Polk HC Jr (1990) Monocyte HLA-DR antigen expression characterizes clinical outcome in the trauma patient. Br J Surg 77:204–207PubMedCrossRef

Ditschkowski M, Kreuzfelder E, Rebmann V, Ferencik S, Majetschak M, Schmid EN, Obertacke U, Hirche H, Schade UF, Grosse-Wilde H (1999) HLA-DR expression and soluble HLA-DR levels in septic patients after trauma. Ann Surg 229:246–254PubMedCrossRef

Satoh A, Miura T, Satoh K, Masamune A, Yamagiwa T, Sakai Y, Shibuya K, Takeda K, Kaku M, Shimosegawa T (2002) Human leukocyte antigen-DR expression on peripheral monocytes as a predictive marker of sepsis during acute pancreatitis. Pancreas 25:245–250PubMedCrossRef

10.

Muehlstedt SG, Lyte M, Rodriguez JL (2002) Increased IL-10 production and HLA-DR suppression in the lungs of injured patients precede the development of nosocomial pneumonia. Shock 17:443–450PubMedCrossRef

11.

Allen ML, Peters MJ, Goldman A, Elliott M, James I, Callard R, Klein NJ (2002) Early postoperative monocyte deactivation predicts systemic inflammation and prolonged stay in pediatric cardiac intensive care. Crit Care Med 30:1140–1145PubMedCrossRef

12.

Bone RC, Balk RA, Cerra FB (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644–1655PubMedCrossRef

13.

McCabe WR, Jackson GC (1962) Gram-negative bacteremia. Arch Intern Med 110:847–864

14.

Le Gall JR, Lemeshow S, Saulnier F (1993) A new Simplified Acute Physiology Score [SAPS II] based on a European/North American multicenter study. JAMA 270:2957–2963PubMedCrossRef

15.

Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S (1998) Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Crit Care Med 26:1793–1800PubMed

16.

Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D (2003) Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 115:529–535PubMedCrossRef

17.

Monneret G, Elmenkouri N, Bohe J, Debard AL, Gutowski MC, Bienvenu J, Lepape A (2002) Analytical requirements for measuring monocytic HLA-DR by flow cytometry: Application to the monitoring of patients with septic shock. Clin Chem 48:1589–1592PubMed

18.

Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, Kox W (1997) Monocyte deactivation in septic patients: Restoration by IFN-gamma treatment. Nat Med 3:678–681PubMedCrossRef

19.

Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M, Early goal-directed therapy collaborative group (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368–1377PubMedCrossRef

20.

Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, Chaumet-Riffaut P, Bellissant E (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862–871PubMedCrossRef

21.

Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr, Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group (2001) Efficacy and safety of recombinant activated protein C for severe sepsis. N Engl J Med 344:699–709PubMedCrossRef

22.

Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM, Surviving Sepsis Campaign Management Guidelines Committee (2004) Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32:858–873PubMedCrossRef

23.

Koppelman B, Neefjes JJ, de Vries JE, de Waal Malefyt R (1997) Interleukin-10 down-regulates MHC class II alphabeta peptide complexes at the plasma membrane of monocytes by affecting arrival and recycling. Immunity 7:861–871PubMedCrossRef

24.

Krakauer T, Oppenheim JJ (1993) IL-1 and tumor necrosis factor-alpha each up-regulate both the expression of IFN-gamma receptors and enhance IFN-gamma-induced HLA-DR expression on human monocytes and a human monocytic cell line (THP-1). J Immunol 150:1205–1211PubMed

25.

Schwiebert LM, Schleimer RP, Radka SF, Ono SJ (1995) Modulation of MHC class II expression in human cells by dexamethasone. Cell Immunol 165:12–19PubMedCrossRef

26.

Basta PV, Moore TL, Yokota S, Ting JP (1989) A beta-adrenergic agonist modulates DR alpha gene transcription via enhanced cAMP levels in a glioblastoma multiforme line. J Immunol 142:2895–2901PubMed

27.

Astiz M, Saha D, Lustbader D, Lin R, Rackow E (1996) Monocyte response to bacterial toxins, expression of cell surface receptors, and release of anti-inflammatory cytokines during sepsis. J Lab Clin Med 128:594–600PubMedCrossRef

28.

Manjuck J, Saha DC, Astiz M, Eales LJ, Rackow EC (2000) Decreased response to recall antigens is associated with depressed co-stimulatory receptor expression in septic critically ill patients. J Lab Clin Med 135:153–160PubMedCrossRef

29.

Wolk K, Docke WD, von Baehr V, Volk HD, Sabat R (2000) Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood 96:218–223PubMed

30.

Piani A, Hossle JP, Birchler T, Siegrist CA, Heumann D, Davies G, Loeliger S, Seger R, Lauener RP (2000) Expression of MHC class II molecules contributes to lipopolysaccharide responsiveness. Eur J Immunol 30:3140–3146PubMedCrossRef

31.

Fumeaux T, Pugin J (2002) Role of interleukin-10 in the intracellular sequestration of human leukocyte antigen-DR in monocytes during septic shock. Am J Respir Crit Care Med 166:1475–1482PubMedCrossRef

32.

Perry SE, Mostafa SM, Wenstone R, Shenkin A, McLaughlin PJ (2003) Is low monocyte HLA-DR expression helpful to predict outcome in severe sepsis? Intensive Care Med 29:1245–1252PubMedCrossRef

33.

Hynninen M, Pettila V, Takkunen O, Orko R, Jansson SE, Kuusela P, Renkonen R, Valtonen M (2003) Predictive value of monocyte histocompatibility leukocyte antigen-DR expression and plasma interleukin-4 and -10 levels in critically ill patients with sepsis. Shock 20:1–4PubMedCrossRef

34.

Lekkou A, Karakantza M, Mouzaki A, Kalfarentzos F, Gogos CA (2004) Cytokine production and monocyte HLA-DR expression as predictors of outcome for patients with community-acquired severe infections. Clin Diagn Lab Immunol 11:161–167PubMedCrossRef

35.

Nakos G, Malamou-Mitsi VD, Lachana A, Karassavoglou A, Kitsiouli E, Agnandi N, Lekka ME (2002) Immunoparalysis in patients with severe trauma and the effect of inhaled interferon-gamma. Crit Care Med 30:1488–1494PubMedCrossRef

36.

Nierhaus A, Montag B, Timmler N, Frings DP, Gutensohn K, Jung R, Schneider CG, Pothmann W, Brassel AK, Schulte Am Esch J (2003) Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. Intensive Care Med 29:646–651PubMed

37.

Docke WD, Hoflich C, Davis KA, Rottgers K, Meisel C, Kiefer P, Weber SU, Hedwig-Geissing M, Kreuzfelder E, Tschentscher P, Nebe T, Engel A, Monneret G, Spittler A, Schmolke K, Reinke P, Volk HD, Kunz D (2005) Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study. Clin Chem 51:2341–2347PubMedCrossRef

Title: Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock
Authors: Guillaume Monneret
Alain Lepape
Nicolas Voirin
Julien Bohé
Fabienne Venet
Anne-Lise Debard
Hélène Thizy
Jacques Bienvenu
François Gueyffier
Philippe Vanhems
Publication date: 01-08-2006
Publisher: Springer-Verlag
Published in: Intensive Care Medicine / Issue 8/2006
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-006-0204-8

2024 ASCO Annual Meeting

Springer Medicine

Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock

Abstract

Objective

Design and setting

Patients

Measurements and results

Conclusion

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Objective

Design and setting

Patients

Measurements and results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2006

Outcome value of Clara cell protein in serum of patients with acute respiratory distress syndrome

Bilateral diaphragm paralysis following cardiac surgery in children: 10-years' experience

Searching for the Holy Grail of the acute respiratory distress syndrome

Low incidence of nephropathy in surgical ICU patients receiving intravenous contrast: a retrospective analysis

Postoperative phrenic nerve palsy: early clinical implications and management

Quality of life after acute respiratory distress syndrome: a meta-analysis